Ironwood Pharmaceuticals (IRWD) Insider Mchugh Buys 63,481 Shares

On June 16, 2026, Julie Mchugh made a notable move by acquiring 63,481 shares of Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD). The stock is currently trading at $3.66.

Insider Buying and Selling at Ironwood Pharmaceuticals, Inc.

Julie Mchugh's purchase of 63,481 shares on June 16 wasn't part of a pre-planned trading program. She wasn't alone in her buying spree; insiders like Shepard Jay, Marla Kessler, Alexander Denner, Catherine Moukheibir, and Jon Duane each bought the same number of shares on the same day.

Other Institutional Activity in Ironwood Pharmaceuticals

In recent institutional moves, BlackRock, Inc. increased its stake in Ironwood Pharmaceuticals by 578,124 shares, bringing its total to 13,362,930 shares valued at approximately $46.9 million. AQR Capital Management LLC also boosted its holdings significantly by 2,811,549 shares, ending with 7,535,080 shares worth about $26.4 million. On the other hand, Sarissa Capital Management LP reduced its position drastically by 6,730,800 shares, now holding 9,188,635 shares valued at $32.3 million.

Ironwood Pharmaceuticals, Inc. Stock Down 19.3%

Shares of Ironwood Pharmaceuticals are trading around $3.66. The company has a market cap of roughly $579.4 million and a P/E ratio of 5.68. Its beta is low at 0.241, indicating less volatility compared to the broader market. Over the past 52 weeks, the stock has seen a low of $0.66 and a high of $5.78. The 50-day moving average is $3.86, while the 200-day moving average is $3.25.

Analysts Set New Price Targets

Analyst activity around Ironwood Pharmaceuticals has been active. On February 26, 2026, Citizens maintained a 'buy' rating with a price target of $10. Meanwhile, Wells Fargo has maintained a 'hold' rating, setting its target at $5 as of January 5, 2026. The consensus among analysts is a 'buy', with an average target price of $6.10.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., based in Boston, MA, is a biotech company focusing on therapies for gastrointestinal and rare diseases. It markets linaclotide for conditions like irritable bowel syndrome and chronic constipation. The company is also developing treatments for visceral pain and short bowel syndrome. Ironwood works with partners like AbbVie and Astellas Pharma to advance its product offerings.

Bottom Line

Julie Mchugh's recent purchase highlights insider confidence in Ironwood Pharmaceuticals. With its strategic partnerships and focus on gastrointestinal therapies, the company remains a key player in its field. Investors will be watching closely, especially with the next earnings report due on August 6, 2026. As always, remember that insider transactions are disclosed post-factum and may not reflect current positions.